|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||9.77 - 10.28|
|52-week range||9.77 - 10.28|
|Beta (5Y monthly)||1.38|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.
FOLD earnings call for the period ending March 31, 2021.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -12.50% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?